A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.
The immunogenicity and protective efficacy of baculovirus recombinant polypeptide based on the Plasmodium falciparum merozoite surface protein 1 (MSP-1) has been evaluated in Aotus lemurinus griseimembra monkeys. The MSP-1-based polypeptide, BVp42, corresponds to the 42-kDa C-terminal processing fragment of the precursor molecule. Immunization of Aotus monkeys with BVp42 in complete Freund's adjuvant resulted in high antibody titers against the immunogen as well as parasite MSP-1. Fine specificity studies indicated that major epitopes recognized by these antibodies localize to conserved determinants of the 19-kDa C-terminal fragment derived from cleavage of the 42-kDa processing fragment. Effective priming of MSP-1-specific T cells was also demonstrated in lymphocyte proliferation assays. All three Aotus monkeys immunized with BVp42 in complete Freund's adjuvant showed evidence of protection of protection against blood-stage challenge with P. falciparum. Two animals were completely protected, with only one parasite being detected in thick blood films on a single days after injection. The third animal had a modified course of infection, controlling its parasite infection to levels below detection by thick blood smears for an extended period in comparison with adjuvant control animals. All vaccinated, protected Aotus monkeys produced antibodies which inhibited in vitro parasite growth, indicating that this assay may be a useful correlate of protective immunity and that immunity induced by BVp42 immunization is mediated, at least in part, by a direct effect of antibodies against the MSP-1 C-terminal region. The high level of protection obtained in these studies supports further development of BVp42 as a candidate malaria vaccine.
Chang
S P
SP
Department of Tropical Medicine and Medical Microbiology, John A. Burns School of Medicine, Honolulu, Hawaii 96816, USA.
Case
S E
SE
Gosnell
W L
WL
Hashimoto
A
A
Kramer
K J
KJ
Tam
L Q
LQ
Hashiro
C Q
CQ
Nikaido
C M
CM
Gibson
H L
HL
Lee-Ng
C T
CT
Barr
P J
PJ
Yokota
B T
BT
Hut
G S
GS
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000917:Antibody Formation; D000918:Antibody Specificity; D000953:Antigens, Protozoan / Q000276:immunology / Q000627:therapeutic use*; D000954:Antigens, Surface / Q000276:immunology / Q000627:therapeutic use*; D016645:Aotidae; D001774:Blood Chemical Analysis; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005069:Evaluation Studies as Topic; D006403:Hematologic Tests; D007111:Immunity, Cellular; D008213:Lymphocyte Activation; D017780:Malaria Vaccines / Q000627:therapeutic use*; D016778:Malaria, Falciparum / Q000517:prevention & control*; D020066:Merozoite Surface Protein 1; D017924:Nucleopolyhedroviruses / Q000235:genetics; D018512:Parasitemia; D010963:Plasmodium falciparum / Q000254:growth & development; D011498:Protein Precursors / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D000954:Antigens, Surface; D017780:Malaria Vaccines; D020066:Merozoite Surface Protein 1; D011498:Protein Precursors; D015800:Protozoan Proteins